Abilify as an Adjunctive Treatment for Refractory Depression
Abilify (Aripiprazole) as an Adjunctive Treatment for Refractory Unipolar Depression
Sponsor: Bristol-Myers Squibb
A PHASE4 clinical study on Depressive Disorder, Major, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Mar 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- St. Luke's-Roosevelt Hospital Center
For direct contact, visit the study record on ClinicalTrials.gov .